Skip to content

Theravance Biopharma TBPH Total Operating Expenses

Total Operating Expenses at other companies

Precigen logo
PrecigenPGEN
$29.25M+22.2%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$949.35M+649%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$37.68M+18.2%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$87.92M+20.0%
XOMA Corporation logo
XOMA CorporationXOMA
$12.8M+28.2%

Segments

By segment

See full
Single Reportable$27.18M-8.9%

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$890.32M+67.5%
Enterprise value$642.72M+37.0%
P/E7.8×
P/S8.1×0.0×

Profitability

See full
Gross margin60.8%
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's total operating expenses?
Theravance Biopharma (TBPH) reported total operating expenses of $27.18M in Q1 2026.
How has Theravance Biopharma's total operating expenses changed year-over-year?
Theravance Biopharma's total operating expenses decreased by 8.9% year-over-year, from $29.82M to $27.18M.
What is the long-term trend for Theravance Biopharma's total operating expenses?
Over 4 years (2021 to 2025), Theravance Biopharma's total operating expenses has grown at a -22.8% compound annual growth rate (CAGR), from $313.1M to $111.07M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.